SpyBiotech has concluded subject enrolment in its Phase I clinical trial of SPYVLP01, a vaccine candidate aimed at human cytomegalovirus (HCMV).

The vaccine leverages the company’s Hepatitis B virus-like particle platform to target HCMV.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial aims to evaluate the safety and immunogenicity of two different doses of the HCMV vaccine.

It enrolled 120 healthy adults aged 18-50 years over a six-month dosing schedule in the UK.

The company stated that an approved vaccine for HCMV does not currently exist.

HCMV, a betaherpesvirus causing lifelong infection, is claimed to have a prevalence rate of 55%-100%, depending on socio-economic and geographical factors.

SpyBiotech focuses on using new vaccine platform technologies to address infectious diseases, cancer, and chronic conditions.

Established in 2017 as a spinout from the University of Oxford by Oxford Science Enterprises (OSE) and Google Ventures (GV), the company secured $32.5m in Series A equity financing in 2021.

Its vaccine platform is based on protein ‘superglue’ technology, which enhances the binding of antigens to vaccine delivery platforms, thereby minimising delivery risk and improving immunogenicity and efficacy.

This technology is claimed to be well-suited for combating infectious diseases in challenging environments and has potential applications in cancer treatment.

SpyBiotech holds sole rights from the University of Oxford to apply, commercialise, and sub-license the SpyTag/SpyCatcher and associated ‘superglue’ technologies for vaccine development.

SpyBiotech CEO Mark Leuchtenberger said: “The end of enrollment in our Phase I trial of SPYVLP01 and the initial promising results both serve as a springboard as we move into the next phase of company development.

“We will continue to progress our scientific pipeline with a focus on our lead candidate and on our EBV-focused collaboration with the University of Oxford.”